Precision BioSciences (DTIL) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

DTIL Precision BioSciences

Watchlist

5.8200
+0.2400+4.30%

Trading Dec 12 14:50 ET

44.65MMarket Cap-20.79P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Gene Editing Market Forecast Report 2024, With Profiles of Merck, GenScript, Revvity, Lonza, Precision BioSciences, Cellectis, AMSBIO, Synthego, Takara Bio, Bio-Techne, Reprocell and More
Yahoo FinanceNov 29 04:43 ET
Precision BioSciences to Participate in Upcoming November Investor Conferences
BusinesswireNov 21 07:01 ET
Precision BioSciences to Present Preclinical PBGENE-HBV Data
TipRanksNov 15 07:10 ET
Express News | Precision BioSciences Inc - Global Study Recruiting Patients, U.S. Ind Expected in 2025
ReutersNov 15 07:00 ET
Express News | Precision BioSciences Inc - Phase 1 Trial Eliminate-B to Assess Safety and Efficacy
ReutersNov 15 07:00 ET
Express News | Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for Pbgene-Hbv for Treatment of Chronic Hepatitis B
ReutersNov 15 07:00 ET

Comments

Jaguar8

Oct 28 06:25

NEWS

$Precision BioSciences (DTIL.US)$
Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024
Precision BioSciences (Nasdaq: DTIL) announced a virtual Hepatitis B Investor Event scheduled for November 15, 2024. The event will feature Key Opinion Leaders and members of Precision's Hepatitis Scientific Advisory Board discussing the current hepatitis B treatment landscape, which only achieves 1-3% func...

Jaguar8

Oct 24 17:27

Put on list. Double good PR today. Low float.

$Precision BioSciences (DTIL.US)$

Jaguar8

Oct 24 17:27

NEWS

$Precision BioSciences (DTIL.US)$
Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress
Precision BioSciences (Nasdaq: DTIL) presented preclinical data at the ESGCT 31st Annual Congress showcasing their ARCUS platform'scapability for high-efficiency gene editing through homology-directed repair (HDR). The research demonstrated gene insertion rates exceeding 85% ...

Jaguar8

Oct 24 07:47

NEWS

$Precision BioSciences (DTIL.US)$
Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B
Precision BioSciences (NASDAQ: DTIL) has received its first Clinical Trial Application (CTA) approval in Moldova for PBGENE-HBV, marking the first in vivo gene editing program for chronic hepatitis B virus to enter global clinical trials. The program aims to cure chronic hepatitis B by eliminating ccc...